Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a 13C-sodium acetate expiration breath test.
Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.
NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax (13C) (the peak time of the 13C-dose-excess curve) (P < 0.05).
Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients. © 2013 International Parkinson and Movement Disorder Society